Video

QUAZAR: Oral Azacitidine Maintenance in AML

Transcript:

Related Videos
David C. Fisher, MD
Farrukh Awan, MD
Minoo Battiwalla, MD, MS
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss long-term data for CPX-351 in acute myeloid leukemia.
James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss factors to help determine intensive chemotherapy fitness in acute myeloid leukemia.
James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss the diagnosis and prevalence of secondary acute myeloid leukemia.
Related Content
FDA Receives NDA for 3-Month Version of Leuprolide Mesylate for Advanced Prostate Cancer
October 30th 2024

FDA Receives NDA for 3-Month Version of Leuprolide Mesylate for Advanced Prostate Cancer

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Daniel DeAngelo MD, PhD, discusses the evolution of management strategies and treatment goals across several hematologic malignancies.
October 29th 2024

The Future of Hematologic Cancer Care Shifts Toward Personalized and Chemotherapy-Free Regimens

Matthew Lunning, DO, FACP
November 30th 2023

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

Harout Semerjian, CEO of GlycoMimetics
October 29th 2024

Uproleselan Plus Chemotherapy Fails to Improve EFS in Older Patients With AML

John F. Seymour, MBBS, FRACP, PhD
October 29th 2024

BGB-16673 Shows Early Activity, Tolerability in Heavily Pretreated Waldenström Macroglobulinemia